Focused On-demand Library for Sphingomyelin phosphodiesterase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

O60906

UPID:

NSMA_HUMAN

Alternative names:

Lyso-platelet-activating factor-phospholipase C; Neutral sphingomyelinase

Alternative UPACC:

O60906; Q5TED1; Q9BWR3

Background:

Sphingomyelin phosphodiesterase 2, also known as Neutral sphingomyelinase and Lyso-platelet-activating factor-phospholipase C, plays a crucial role in cellular processes by catalyzing the hydrolysis of sphingomyelin to ceramide and phosphocholine. Its activity extends to hydrolyzing lyso-platelet-activating factor and sphingosylphosphocholine, impacting cellular signaling pathways.

Therapeutic significance:

Understanding the role of Sphingomyelin phosphodiesterase 2 could open doors to potential therapeutic strategies. Its involvement in key biochemical pathways underscores its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.